NEW YORK–(BUSINESS WIRE)–VanEck announced today its regular distribution per share for its VanEck
Vectors Pharmaceutical ETF.
|October 3, 2016||October 5, 2016||October 7, 2016|
|VanEck Vectors Pharmaceutical ETF||Quarterly||$||0.2148|
The majority, and possibly all, of the dividend distributions will be
paid out of net investment income earned by the Funds. A portion of
these distributions may come from net short-term or long-term realized
capital gains or return of capital.
The final tax treatment of these dividends will be reported to
shareholders on their 1099-DIV form, which is mailed after the close of
each fiscal year. The amount of dividends paid by each ETF may vary from
time to time. Past amounts of dividends are no guarantee of future
dividend payment amounts.
IRS Circular 230 disclosure: VanEck does not provide legal, tax
or accounting advice. Any statement contained in this communication
concerning U.S. tax matters is not intended or written to be used, and
cannot be used, for the purpose of avoiding penalties imposed on the
relevant taxpayer. Shareholders or potential shareholders of the VanEck
Vectors ETFs should obtain their own independent tax advice based on
their particular circumstances.
If you have any questions concerning this information or the VanEck
Vectors ETFs in general, please call 800.826.2333 between 9:00 a.m. and
5:30 p.m., Monday through Friday.
VanEck’s mission is to offer intelligently designed investment
strategies that take advantage of targeted market opportunities. Founded
in 1955, the firm is a pioneer in global investing with a history of
placing clients’ interests first in all market environments. Today,
VanEck continues this tradition by offering innovative active and
passive investment portfolios in hard assets, emerging markets equity
and debt, precious metals, fixed income, and other alternative asset
classes. VanEck Vectors exchange-traded products are one of the largest
ETP families in the world, managing more than 70 funds that span a range
of sectors, asset classes, and geographies. As of August 31, 2016,
VanEck managed approximately $38.1 billion in assets, including mutual
funds, ETFs, and institutional accounts.
Please call 800.826.2333 or visit our website for the most recent
month-end performance of VanEck Vectors ETFs. This information will be
available no later than seven business days after the most recent month
The principal risks of investing in VanEck Vectors ETFs include sector,
market, economic, political, foreign currency, world event, index
tracking and non-diversification risks, as well as fluctuations in net
asset value and the risks associated with investing in less developed
capital markets. The assets of some Funds may be concentrated in a
particular sector and may be subject to more risk than investments in a
diverse group of sectors. The Funds may loan their securities, which may
subject them to additional credit and counterparty risk. Please see
the Prospectus and Summary Prospectus of the Fund for more complete
information regarding its specific risks.
The “net asset value” (NAV) of an ETF is determined at the close of each
business day, and represents the dollar value of one share of the ETF;
it is calculated by taking the total assets of an ETF subtracting total
liabilities, and dividing by the total number of shares outstanding. The
NAV is not necessarily the same as an ETF’s intraday trading value.
Investors should not expect to buy or sell shares at NAV. Total returns
are based upon closing “market price” (price) of the ETF on the dates
Fund shares are not individually redeemable and will be issued and
redeemed at their NAV only through certain authorized broker-dealers in
large, specified blocks of shares called “creation units” and otherwise
can be bought and sold only through exchange trading. Creation units are
issued and redeemed principally in kind. Shares may trade at a premium
or discount to their NAV in the secondary market. You will incur
brokerage expenses when trading Fund shares in the secondary market.
Investors may call 800.826.2333 or visit vaneck.com
for a free prospectus
prospectus. Investing involves risk, including
possible loss of principal. Bonds and bond funds will decrease in value
as interest rates rise. An investor should consider the investment
objective, risks, and charges and expenses of VanEck Vectors ETFs
carefully before investing. The prospectus and summary prospectus
contains this and other information. Please read the prospectus and
summary prospectus carefully before investing.
Mike MacMillan / Chris Sullivan,